# Do GLP-1 Drugs Cause Arrhythmia? Three Intervals, Two Cross One | This GLP Do GLP-1 drugs cause arrhythmia? Ten tirzepatide trials gave an atrial fibrillation odds ratio of 2.20, credible interval 0.81 to 6.75 | and ten reviews disagree. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia Updated: 2026-09-18 Published: 2026-09-17 [← Research](https://thisglp.com/research) Safety # Do GLP-1 Drugs Cause Arrhythmia? Three Intervals, Two Cross One Pooled across ten tirzepatide trials, the odds ratios for arrhythmia all sat above 1. Only the broadest category cleared significance, and barely. Ten meta-analyses of the same drug class point the other way, and none of them reached moderate confidence. [This GLP Editorial Team](https://thisglp.com/about)September 20268 min read Odds ratio vs comparator, 95% credible interval · atrial fibrillation · atrial arrhythmia · any arrhythmia · 1.0 · 10 trials, 6,515 people — intervals this wide mean few events **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). The evidence points both ways. Pooled across ten randomized tirzepatide trials, atrial fibrillation came out at an odds ratio of 2.20 [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia#ref-1). Its credible interval runs from 0.81 to 6.75, which measures nothing. Ten meta-analyses of this drug class point the other way, toward less atrial fibrillation [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia#ref-2). None of them reached moderate confidence. A network comparison of 2,171,267 patients found no difference against a near-neutral drug [\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia#ref-3). ## Key takeaways - A meta-analysis pooled 10 randomized trials of tirzepatide covering 6,515 people, 68.9% of them randomized to the drug. - Atrial fibrillation: odds ratio 2.20, 95% credible interval 0.81 to 6.75. - Atrial arrhythmia: 2.16, credible interval 0.90 to 5.87. Both intervals include no effect. - Any arrhythmia: 1.84, credible interval 1.04 to 3.90 — the only one that excludes it. - An umbrella review of ten meta-analyses pointing the other way rated five at low confidence and four at critically low. This is the safety question, not the treatment one. Whether a GLP-1 keeps atrial fibrillation from returning after ablation is a separate matter. The answer there is also unsettled, and it is set out in [the atrial fibrillation evidence](https://thisglp.com/research/do-glp1-drugs-help-atrial-fibrillation). ## What was pooled Ten randomized controlled trials of tirzepatide in adults with overweight or obesity [\[1\]](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia#ref-1). In total 6,515 people, of whom 4,491 — 68.9% — were randomized to the drug. The analysis was Bayesian, so its ranges are credible intervals rather than confidence intervals. It looked at three nested categories of rhythm problem. For atrial fibrillation the pooled odds ratio was 2.20, credible interval 0.81 to 6.75. For atrial arrhythmia more broadly, 2.16, credible interval 0.90 to 5.87. For any arrhythmia at all, 1.84, credible interval 1.04 to 3.90. ## How to read intervals that wide A range from 0.81 to 6.75 is not a measurement. It is consistent with a slight reduction and with a sevenfold rise. It cannot tell those apart. Intervals get that wide when there are very few events. That is what arrhythmia looks like in trials designed to measure weight. So the two narrower categories found nothing. The broadest one did, barely, at a lower bound of 1.04. One more trial in either direction could undo it. What an interval includes decides more here than the point estimate does, the same reading applied in [the vessel-function measurements](https://thisglp.com/research/do-glp1-drugs-improve-blood-vessel-function). A composite collects events “Any arrhythmia” is a composite, and composites collect more events, which narrows intervals. There are two honest readings and this page picks neither. One: a real effect is spread across rhythm disturbances and only becomes visible when they are counted together. Two: three related analyses were run and the one with the most events came out significant, which is what multiplicity does. ## The literature that points the other way Ten meta-analyses have asked whether this drug class lowers atrial fibrillation. An umbrella review appraised them together [\[2\]](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia#ref-2). Two shared an identical six-study base and reported hazard ratios of 0.58 and 0.78. Identical evidence, different published answers. Overlap between the reviews was substantial: 43.8% for recurrence and 34.1% among the semaglutide-only incident reviews. So when these papers agree, the agreement is largely a shared base rather than independent replication. Five were rated low confidence and four critically low. None reached moderate or high. The full appraisal is in [the umbrella review](https://thisglp.com/research/glp1-two-meta-analyses-same-six-trials). The largest single comparison sits between the two positions. A network and pairwise meta-analysis covered 2,171,267 patients with type 2 diabetes [\[3\]](https://thisglp.com/research/do-glp1-drugs-cause-arrhythmia#ref-3). It found GLP-1 drugs no different from DPP-4 inhibitors on new-onset atrial fibrillation, at RR 0.93. SGLT2 inhibitors beat both. That is not a signal of harm and it is not a benefit either. ## What would make this more than a signal A trial with arrhythmia as a prespecified endpoint. Monitoring designed to catch it. Enough events to produce an interval narrower than a factor of eight. None of that exists. What exists is adverse-event reporting pooled after the fact. There is also a confounder running in an awkward direction. Rapid weight loss, electrolyte shifts and a rising heart rate all accompany these drugs. All three have some relationship to rhythm. A pooled adverse-event count cannot say whether any of it is doing the work. Nor can a trial population answer questions about a clinic population, the gap measured in [the ordinary-care results](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). ## What to do with it Not stop a prescribed drug on the strength of it. Three wide intervals from pooled adverse events are not a reason to change treatment. That decision belongs to a prescriber who knows your heart history. What it is worth is a question. A history of atrial fibrillation, palpitations or any rhythm diagnosis belongs on an intake form before starting. It is exactly the kind of history a telehealth questionnaire may not ask for. [The census of what sellers leave unasked](https://thisglp.com/research/what-glp1-sellers-do-not-publish) counts that from the other side. ## Frequently asked Do GLP-1 drugs cause arrhythmia? Nothing here settles it. Pooled across ten tirzepatide trials, atrial fibrillation came out at an odds ratio of 2.20 with a credible interval from 0.81 to 6.75, which is consistent with a small reduction and with a sevenfold rise. Which result was statistically significant? Only the broadest category. Any arrhythmia gave 1.84, credible interval 1.04 to 3.90. The two narrower categories both crossed no effect. Does other evidence disagree? Yes. Ten meta-analyses point toward less atrial fibrillation, though an umbrella review rated five of them low confidence and four critically low. A comparison of 2,171,267 patients found no difference against DPP-4 inhibitors. Should someone with a rhythm problem avoid these drugs? That is a prescriber's decision, not a conclusion from pooled adverse events. A history of atrial fibrillation or palpitations belongs on an intake form before starting. ## Sources 1. \[1\] Mansouri ES, et al. (2026). Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials Journal of the American Heart Association. [PMID 42714458](https://pubmed.ncbi.nlm.nih.gov/42714458/) 2. \[2\] Ramzy D, et al. (2026). Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses Cureus. [PMID 42668799](https://pubmed.ncbi.nlm.nih.gov/42668799/) 3. \[3\] Ye X, Wu Q, Hou L, Hou X, Yang Y, Yang C, Huang M, Wang S (2026). Network and Pairwise Meta-Analysis of the Association Between Novel Hypoglycemic Agents and Atrial Fibrillation Risk in Patients With Type 2 Diabetes Mellitus Diabetes/Metabolism Research and Reviews. [PMID 42455922](https://pubmed.ncbi.nlm.nih.gov/42455922/) ## More in Safety - [ Medication list · Check combinations · Fluid loss · Changes kidney risk · Pharmacist · Choose a safe option ### Can You Take Ibuprofen With Ozempic? Check Kidney and Stomach Risks ](https://thisglp.com/research/can-you-take-ibuprofen-with-ozempic) - [ 1.9% · Placebo · 8.5% · Ozempic 0.5 mg · 8.8% · Ozempic 1 mg ### Does Ozempic Cause Diarrhea? Rates, Timing, and When to Call ](https://thisglp.com/research/does-ozempic-cause-diarrhea) - [ Sit down · Prevent a fall · Check context · Glucose and fluids · Get help · Severe symptoms ### Does Ozempic Cause Dizziness? What to Check First ](https://thisglp.com/research/does-ozempic-cause-dizziness)